Menu
Search
|

Menu

Close
X

Cellect Biotechnology Ltd APOP.OQ (NASDAQ Stock Exchange Capital Market)

4.03 USD
+0.12 (+3.07%)
As of Nov 20
chart
Previous Close 3.91
Open 3.71
Volume 2,287
3m Avg Volume 3,665
Today’s High 4.03
Today’s Low 3.70
52 Week High 13.50
52 Week Low 3.70
Shares Outstanding (mil) 111.91
Market Capitalization (mil) 185.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, ILS)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (ILS)
FY18
-0.074
FY17
-0.179
FY16
-0.181
FY15
-0.135
*Note: Units in Millions of Shekel
**Note: Units in Shekel

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
12.06
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-144.94
15.05
Return on Equity (TTM)
vs sector
-182.75
16.62

EXECUTIVE LEADERSHIP

Nuriel Kasbian
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Shai Yarkoni
Chief Executive Officer, Director, Since 2013
Salary: --
Bonus: --
Eyal Leibovitz
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Amotz Nehushtan
Vice President - Research & Development & Product Development, Since 2016
Salary: --
Bonus: --
Yaron Pereg
Chief Development Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

23 Ha'Taas St.
KFAR SAVA     4442525

Phone: +9729.9741444
Site: cellect.co

Cellect Biotechnology Ltd, formerly Cellect Biomed Ltd, is an Israel-based company engaged in regenerative medicine through the development of products facilitating immune stem cell selection. The Company’s platform technology is based on the game changing perception that the functional properties of stem cells rather than appearance should be used for their identification, selection and utilization. The Company’s first product is designed to harness the critical function of sensitivity to specific apoptosis-inducing agents. While these molecules induce apoptosis (programmed cell death) in mature cells, they spare stem cells. This differential sensitivity is used to improve the outcome of bone marrow transplantation mainly by eliminating severe adverse effects.

SPONSORED STORIES